pre-IPO PHARMA

COMPANY OVERVIEW

Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a newly established biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment. The Company is applying the latest scientific insights and expertise in drug development to advance novel immuno-oncology products and bring new treatment options to cancer patients.


LOCATION

  • Palo Alto, CA, USA

  • THERAPEUTIC AREAS

  • Immunology
  • Oncology

  • WEBSITE

    https://www.immune-onc.com/home.html


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Jun 7, 2023

    Immune-Onc Therapeutics Presents IO-202 Phase 1 Data in Patients with Relapsed or Refractory AML and CMML at the EHA Annual Meeting 2023


    Apr 14, 2023

    Immune-Onc Therapeutics to Present Encouraging Phase 1 Data for IO-108 at AACR Annual Meeting 2023


    Mar 14, 2023

    Immune-Onc Therapeutics Announces IO-108 Phase I Clinical Trial Results Selected for Oral Presentation at AACR Annual Meeting 2023


    Mar 3, 2023

    Immune-Onc Therapeutics to Showcase Leadership in Myeloid Biology and Drug Development at Upcoming Scientific and Investor Conferences


    Jan 5, 2023

    Immune-Onc Therapeutics Announces Close of Series B Extension Financing, Bringing Total Round to $131 Million


    For More Press Releases


    Google Analytics Alternative